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Multi-country Stem Cell Trials: the need for an International Support Structure  
 
 
 
Introduction 
 
Regenerative stem cell research is now rapidly moving toward the clinic and 
routine medical applications. With the number of Phase II and III trials growing, 
the conduct of multi-country clinical research collaborations is becoming 
increasingly important. These partnerships accelerate processes of clinical 
translation, and form the basis for marketing approval of new therapies in 
multiple countries (Martell et al., 2010). At present, however, the conduct of 
international stem cell trials is hampered by a high level of regulatory 
heterogeneity across countries, and the absence of internationally harmonized 
governance frameworks (Bubela et al., 2014). Even though drug regulatory 
authorities in the USA, the European Union and Canada have now initiated 
collaborations that focus on the convergence of regulatory procedures for 
cellular therapy products, globally harmonized regulatory procedures are far-off 
(Arcidiacono et al., 2013). Japan for instance, has recently introduced a fast-track 
approval path for stem cell therapies (Cyranoski, 2013), and in China and India 
drug regulatory agencies have at present only issued provisional regulations and 
regulatory guidelines whose legal power is limited (Sleeboom-Faulkner and Patra 
2011; Rosemann 2013). But complications arise also from the ongoing growth of 
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unregulated stem cell treatments that are offered to patients without systematic 
proof of safety and efficacy in many countries (Lysaght and Sipp 2014; Ogbogu et 
al. 2013). Lucrative business opportunities and the existence of regulatory grey 
areas have given rise to uncontrolled applications and the emergence of transnational 
entrepreneurial networks that advocate alternative forms of research regulation. 
Professional associations such as the International Cellular Medicine Society (ICMS), 
for example, have developed their own guidelines and IRB and accreditation services 
(Blasimme 2012). These activities support experimental for-profit interventions with 
stem cells outside of the methodological format of the randomized controlled trial and 
independent from the review procedures of drug regulatory agencies (Rosemann, 
under review). This diversification of clinical research standards within and across 
countries makes efforts of international harmonization increasingly difficult.  
In Part I of this paper I will introduce four central challenges to the 
organization of international stem cell trials that emerge from this high level of 
regulatory variation. These obstacles apply in principle to all innovative multi-country 
stem cell trials that are subject to approval by a drug regulatory authority, including 
trials with (minimally manipulated) autologous stem cells. These challenges are 
especially pronounced, however, in the case of trials with pluripotent stem cells that 
involve increased technical complexity and higher risks for patients. Exceptions 
are trials that involve established stem cell treatments (such as the use of 
hematopoietic stem cells for leukemia), or studies that make use of autologous stem 
cells that are less than minimally manipulated and not subject to regulatory scrutiny 
(Li et al. 2014). Then in Part II I will argue for the need of an international support 
structure that systematically addresses these problems. In this regard, I will introduce 
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five measures that may help to reduce existing difficulties and to conduct 
international stem cell trials in a more effective and cost-efficient way.  
 
Challenges to the organization of multi-country stem cell trials 
 
A first challenge to the organization of multi-country stem cell trials is the necessity 
to conduct long-term in-depth research into the regulatory requirements of drug 
regulatory authorities in multiple countries (OECD, 2011). Stem cell therapies, as 
pointed out by Martell and colleagues ‘do not neatly fit into current regulatory 
categories’, and the barriers of translating stem cell-based approaches in functioning 
therapies lie ‘in both technical and regulatory constraints’ (Martell et al. 2010: 451). 
Regulations for the clinical use of stem cells are in many countries emerging only 
gradually and far-reaching regulatory differences exist. For clinical investigators 
and industry this diversified and rapidly changing situation is confusing and poses 
significant organizational difficulties (Rosemann 2014a). What is required is a long-
term, reflective engagement with the review and approval procedures that are handled 
by the drug regulatory authorities in the countries in which a trial is conducted. In 
order to develop study protocols that are compliant with the demands of multiple 
regulatory agencies, gaps between jurisdictional frameworks must be identified at an 
early stage of the clinical translation process. This is a difficult task that takes time 
and may be complicated by language barriers, insufficiently defined regulatory 
procedures, cultural differences and disparities in the enforcement of regulatory 
protocols (Ravinetto et al., 2013). It is complicated, furthermore, because the 
regulatory issues that are associated with the development of autologous stem cell 
therapies (Hourd et al. 2014) do in important respects differ from the characteristics 
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that need to be taken into account in the context of clinical trials with pluripotent stem 
cells (Andrews et al. 2014). 
A second challenge is that the interaction with medical authorities in multiple 
countries is resulting in a very high level of organizational complexity (Minisman et 
al., 2012). To file applications at multiple drug regulatory agencies is a time, cost and 
labor-intensive process that requires specially trained staff and a well-functioning 
administrative infrastructure (2014). While for industry-sponsored trials this is not 
necessarily a problem, for academic research groups and small-to-mid size biotech 
companies (which at present are the main sponsors of clinical stem cell trials) these 
resources are often not available and difficult to acquire (Keirstead, 2012).  
A third type of challenge are time delays, increased costs and uncertainties 
that arise from non-existent or still emerging regulatory procedures in some countries. 
In China, for instance, where effective regulatory procedures for the clinical testing of 
stem cell-based therapeutic approaches have until 2012 been non-existent, the China 
Food and Drug Administration (CFDA) has repeatedly refused to accept incoming 
investigational new drug (IND) applications for stem cell-based products (Rosemann 
2013). Such unresolved regulatory issues can cause long-drawn-out delays and 
additional costs to the sponsors of clinical stem cell trials, and result in the need to 
apply for regulatory approval in another country where regulatory procedures are 
clearer, and to conduct the trial there (Bhagavati, 2014). But unresolved regulatory 
issues and the potential for sudden regulatory changes exist also in countries with 
highly developed regulatory frameworks. Noteworthy is, in particular, the ongoing 
debate on who should regulate autologous stem cell interventions (Zarzeczny et al. 
2014). In the USA, for instance, think tanks are using the case of autologous stem 
cells in order to promote broader deregulation and several companies and professional 
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societies (most prominently the ICMS) have argued that ‘autologous cell products 
should be treated as part of medical practice and thus not subjected to marketing 
approval’ (Bianco and Sipp 2014). These calls have resulted in a bill for the Freedom 
of Choice Act that was put forward to the US congress in April 2014. According to 
this bill investigational stem cell technologies could be sold to terminally ill patients, 
outside of the control of the US Food and Drug Administration (FDA) (Morgan 
2014). Similar developments can also be reported from other highly regulated 
countries. Australia, for instance, has exempted autologous stem cells from the review 
procedures of its drug regulatory agency (Tuch and Wall 2014) and in Italy the use of 
autologous mesenchymal stem cells has been taken out of the jurisdiction of the 
Italian Medicine’s Agency in 2013 (Berger et al. 2014). These developments are 
likely to influence regulations in other countries (Bianco and Sipp 2014). Most 
importantly, however, the jurisdictional variation in regulatory frameworks and the 
prospect of ongoing policy changes make the implementation of multi-country stem 
cell trials more difficult and increase the risk of organizational complications, 
unexpected or misplaced investments and time delays. 
A fourth challenge is that the high level of regulatory variation across 
countries necessitates far-reaching forms of scientific self-governance, training and 
procedural adjustments in participating clinical trial sites (Rosemann, 2014b). A 
central reason for this is, that the existence of regulatory differences between national 
jurisdictions is reflected in contrasts of clinical research practices and methodologies, 
at the level of local medical institutions. In many countries, moreover, knowledge on 
the conduct of systematized controlled stem cells trials is often limited among clinical 
researchers (Li et al., 2014). These disparities between and also within local hospitals 
form a clear threat to the scientific integrity of international stem cell trials (OECD, 
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2011). As a result, intensive forms of staff training and adjustments of local clinical 
research practices are necessary, so that standardized research protocols can be 
implemented (Ravinetto et al., 2013). Standardization requires, furthermore, the 
implementation of reliable monitoring and control infrastructures. For academic 
investigators and small-to-mid size companies the performances of these tasks, poses 
a significant organizational and financial burden (Keirstead, 2012). Unless sufficient 
funding for these forms of education and scientific self-governance is acquired, multi-
center international stem cell trials cannot be conducted.  
 
The need for an international support structure  
 
The International Society of Stem Cell Research (ISSCR) has in 2010 called for the 
need to harmonize regulations for the clinical translation and commercialization of 
stem cell-based products and therapies (Martell et al., 2010). However, in 2014 the 
global regulatory landscape for clinical stem cell research remains as diverse as 
before. This situation continues to pose problems to the organization of transnational 
stem cell trials. What is needed in order to improve this situation is the creation of an 
international support structure, through which the organizational challenges of multi-
country stem cell trials can be systematically addressed. International bodies such as 
the ISSCR or the International Stem Cell Forum have until now focused primarily on 
the development of guidelines, best practice standards and various types of 
recommendation. These documents have concentrated on crucial aspects of the 
clinical translation process, including the collection, derivation, storage and clinical 
application of stem cells, as well as intellectual property rights, commercialization, 
industry engagement and ethical issues of stem cell research (Isasi, 2012). However, a 
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support structure that specifically addresses the regulatory and organizational 
challenges of multi-country stem cell trials has so far not yet been developed. Such a 
scheme could encompass five elements:  
 
1. The development of a web-based databank that provides detailed information 
on regulatory requirements and procedures for clinical stem cell research and 
marketing approval in a large number of countries 
 
This repository could provide a detailed overview of responsible government 
units, key contacts, as well as regulatory documents and websites. Regulatory 
procedures and manuals on how to apply for and conduct stem cell clinical 
trials in different countries could be introduced in detail. This databank could 
work with a computerized system that explains differences between the 
regulatory requirement of specific countries and regions, and that helps to 
clarify what kind of tasks clinical trial sponsors will have to perform to 
balance out these regulatory gaps. In order to be valuable, such a database 
would have to be nuanced for different cell types and manufacturing 
standards. It would also have to provide information for the regulation of 
combination therapies (such as cell therapy-drug or cell therapy-device) where 
different regulatory pathways are required for each element.    
 
2. The establishment of an international task force that identifies the central 
challenges to multi-country stem cell trials  
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This task force could consist of researchers and sponsors with experience in 
the organization of multi-country trials. It should strive for the identification 
of the key challenges for the clinical translation of stem cell-based therapies in 
the context of international projects. Such a task force could aim, furthermore, 
for the development of solution strategies through which international stem 
cell trials can be conducted in a more time and cost efficient way. These 
measures could include, for example, information packages for sponsors and 
clinical investigators, as well as tools for staff training, project management 
and data collection. Such a task force could be initiated by the ISSCR, the 
International Stem Cell Forum (ISCF), or another international society such as 
the International Society of Cellular Therapies (ISCT). 
 
3. The creation of an interactive online education and discussion platform  
 
The establishment of an interactive education and discussion platform would 
allow for the sharing of critical information and experiences of clinical trial 
sponsors and investigators. Scientists or sponsors who plan to conduct 
international stem cell trials can learn in this way from the experiences of 
other researchers, and make practice-based assessments of the tasks, costs, 
timeframes and challenges that may lie ahead of them. Such knowledge could 
also help to make well-informed budgetary estimations, and to gain access to 
other useful information such as information about insurance schemes, the 
implementation of project-internal monitoring systems, and ethics committee 
approval (Ravinetto et al., 2013). 
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4. Raise awareness of the challenges of multi-country stem cell trials among 
public, private and charitable funding bodies  
 
To facilitate international collaborations in the stem cell field, it will be 
important to create an awareness of the challenges of multi-country stem cell 
trials among public, private and charitable funding bodies. To develop an 
understanding of these problems will be crucial to prevent unrealistic 
expectations, and to obtain additional money that is required to tackle the 
challenges associated with international stem cell trials. A first step into this 
direction has been made by researchers at the University of Alberta in Canada, 
together with colleagues from McGill University, the University of British 
Columbia and the London Regenerative Medicine Network (Bubela et al. 
2012). This group has founded the interactive online forum ‘Enabling 
Advanced Cell Technologies (EnACT)’ [http://enactforum.org], that offers an 
interactive, moderated discussion platform that aims to develop ‘solutions to 
key non-science barriers’ to the clinical translation of cell and stem cell-based 
treatment pathways (Bubela et al. 2012). The EnACT website features twelve 
thematic areas where barriers to translational stem cell research emerge. 
However, the challenges for the organization of multi-country clinical trial 
collaborations are not discussed on the forum. Moreover, online forums may 
not be the best way to identify and /or raise awareness of the challenges of 
international stem cell trials. The organization of a series of workshops and 
publications that could be organized by the ISSCR, the ISCF, the ISCT or 
another professional organization promises to be a more efficient method. 
Ideally, such workshops would involve representatives from public as well as 
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charitable funding bodies, the industry and drug regulatory agencies from 
multiple countries. 
 
5. Promote forms of regulatory harmonization and lobby for better 
communication between drug regulatory authorities 
 
A final field of activity would be the promotion of forms or regulatory 
harmonization or at least, to lobby for better communication between drug 
regulatory authorities, so that some of the challenges regarding multi-country 
stem cell trials can be prevented or reduced. Harmonization, as recently 
pointed out in a position paper of the US FDA’s Office of Cellular, Tissue, 
and Gene Therapies, does not necessarily imply the production of 
internationally shared consensus guidelines (as in case of the ICH-GCP 
standards). Harmonization can refer too to the partial convergence of 
regulatory perspectives – but based on the independent development of 
national regulations and guidelines (Arcidiacono et al., 2012). In the light of 
the current level of regulatory divergence in the clinical stem cell field, it is 
questionable whether such a convergence perspective could really be 
achieved. Be this as it may, considering the existing challenges for the 
performance of international stem cell trials, the move toward a more coherent 
and predictable international regulatory landscape would clearly be 
advantageous. 
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Conclusions  
 
While there is little doubt that the introduction of such an international support 
structure for multi-country stem cell trials would be of great value, its feasibility must 
be viewed from the perspective of possible sponsors. Considering the high costs of 
clinical translation it is to be expected that the greater part of Phase III trials will 
involve commercial sponsors. A newly devised support structure, therefore, must be 
of use to both academic investigators and corporate sponsors. Ideally, representatives 
of both groups will be involved in the design of these measures. It is not unlikely 
though, that commercial sponsors may prefer to undertake their own work into the 
regulatory barriers of international stem cell trials, for instance by external regulatory 
affairs consultants that help companies to navigate and identify existing challenges. 
For fear of competition these corporations may not be willing or able to share this 
information through online forums, publications or other means. At present, however, 
the majority of clinical trials in the stem cell field are either investigator-initiated or 
trials that are organized by small to mid-size biotech companies, often startups that 
operate under high risks. The financial means of both of these groups are usually 
limited. Moreover the time and organizational capacities – especially of academic 
investigators are highly restricted. For these groups a support structure in which many 
of the question and practical challenges that emerge in the context of multi-country 
stem cell trials are discussed and anticipated will allow to save costs, time and 
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facilitate realistic assessments and planning. A problem is, of course, that such 
initiatives are likely to be expensive. The organization of such a support structure 
should best lie in the hands of an international professional society such as the 
International Society for Stem Cell Research or the International Society of Cellular 
Therapies, which are large scale organizations that represent large numbers of 
researchers in many countries and that also cater the interests of the industry. 
Alternatively, the International Stem Cell Forum – which brings together some of the 
main public funding bodies for stem cell research around the world – would be a 
suitable umbrella organization for such an initiative. These organizations are firmly 
grounded into the international scientific community and have a high level of 
credibility. Most importantly, they are most likely to reach a large number of 
interested stakeholders and it also is in the interest of these institutions to provide up-
to-date information, to stimulate participation and to disseminate findings from such 
an initiative. These large international organizations are also in the best position to 
attract the funding for such a transnational support structure, and to provide an 
apposite organizational platform. Considering the high expenses and financial risks of 
multi-country stem cell trials and the potential for regulatory misassessments and 
long-drawn-out delays, the money for such an international support structure seems 
well invested. 
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Highlights 
 
 The paper tackles the organizational challenges of international stem cell 
trials   
 It explores the obstacles that result from regulatory variation across 
countries 
 The article argues for the formation of an international support structure 
 Such a structure will be of use to academic and corporate trial sponsors 
 Five steps through which such a support structure could be realized are 
introduced 
